Marksans Pharma Yönetim
Yönetim kriter kontrolleri 2/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Mark Saldanha
İcra Kurulu Başkanı
₹68.9m
Toplam tazminat
CEO maaş yüzdesi | 69.7% |
CEO görev süresi | 9.1yrs |
CEO sahipliği | 43.8% |
Yönetim ortalama görev süresi | 13yrs |
Yönetim Kurulu ortalama görev süresi | 6.3yrs |
Son yönetim güncellemeleri
Recent updates
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Oct 24Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Sep 21Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | ₹3b |
Mar 31 2024 | ₹69m | ₹48m | ₹3b |
Dec 31 2023 | n/a | n/a | ₹3b |
Sep 30 2023 | n/a | n/a | ₹3b |
Jun 30 2023 | n/a | n/a | ₹3b |
Mar 31 2023 | ₹52m | ₹48m | ₹3b |
Dec 31 2022 | n/a | n/a | ₹2b |
Sep 30 2022 | n/a | n/a | ₹2b |
Jun 30 2022 | n/a | n/a | ₹2b |
Mar 31 2022 | ₹38m | ₹35m | ₹2b |
Dec 31 2021 | n/a | n/a | ₹2b |
Sep 30 2021 | n/a | n/a | ₹2b |
Jun 30 2021 | n/a | n/a | ₹3b |
Mar 31 2021 | ₹10m | ₹10m | ₹2b |
Dec 31 2020 | n/a | n/a | ₹2b |
Sep 30 2020 | n/a | n/a | ₹2b |
Jun 30 2020 | n/a | n/a | ₹1b |
Mar 31 2020 | ₹10m | ₹10m | ₹1b |
Dec 31 2019 | n/a | n/a | ₹879m |
Sep 30 2019 | n/a | n/a | ₹834m |
Jun 30 2019 | n/a | n/a | ₹780m |
Mar 31 2019 | ₹10m | ₹10m | ₹804m |
Dec 31 2018 | n/a | n/a | ₹666m |
Sep 30 2018 | n/a | n/a | ₹582m |
Jun 30 2018 | n/a | n/a | ₹463m |
Mar 31 2018 | ₹12m | ₹10m | ₹358m |
Tazminat ve Piyasa: Mark 'nin toplam tazminatı ($USD 818.85K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 471.41K ).
Tazminat ve Kazançlar: Mark 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Mark Saldanha (52 yo)
9.1yrs
Görev süresi
₹68,857,053
Tazminat
Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Non-Independent Executive Chairman & MD | no data | ₹68.86m | 43.8% ₹ 57.9b | |
Chief Financial Officer | 22.2yrs | ₹12.84m | Veri yok | |
Director Operations | no data | ₹5.80m | Veri yok | |
Company Secretary | 15.8yrs | ₹2.84m | Veri yok | |
Whole-Time Executive Non Independent Director | 10.2yrs | ₹7.07m | 0.073% ₹ 96.4m | |
Whole-Time Executive Non Independent Director | 5.8yrs | ₹18.75m | Veri yok | |
Senior Vice President of QC | no data | ₹10.61m | Veri yok | |
Managing Director of Australia Operations | no data | Veri yok | Veri yok | |
Managing Director of UK Operations | no data | Veri yok | Veri yok | |
Chief Operating Officer of US Operations | no data | ₹10.29m | Veri yok |
13.0yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş
Deneyimli Yönetim: MARKSANS 'un yönetim ekibi deneyimli ve deneyimlidir ( 13 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Non-Independent Executive Chairman & MD | 9.1yrs | ₹68.86m | 43.8% ₹ 57.9b | |
Whole-Time Executive Non Independent Director | 10.2yrs | ₹7.07m | 0.073% ₹ 96.4m | |
Whole-Time Executive Non Independent Director | 5.8yrs | ₹18.75m | Veri yok | |
Non-Executive & Non-Independent Director | 3.3yrs | Veri yok | Veri yok | |
Non-Executive & Independent Director | 5.3yrs | ₹15.00k | Veri yok | |
Non-Executive & Independent Director | 1.5yrs | ₹300.00k | Veri yok | |
Non-Executive & Independent Director | 13.1yrs | ₹25.00k | Veri yok | |
Non-Executive Independent Director | 6.7yrs | ₹400.00k | Veri yok |
6.3yrs
Ortalama Görev Süresi
53.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: MARKSANS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).